Complete Filing Data
Metagenomi Therapeutics, Inc. reported Stockholders Equity of $158.60 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Metagenomi Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income * | -$87.9M | -$78.1M | -$68.3M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$449.0K | $806.0K | $177.0K |
| Revenue From Contract With Customer Excluding Assessed Tax | $25.2M | $52.3M | $44.8M |
| Research And Development Expense | $94.4M | $109.2M | $94.4M |
| Other Nonoperating Income Expense | -$91.0K | -$207.0K | -$74.0K |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$449.0K | $806.0K | $177.0K |
| Operating Income Loss | -$96.0M | -$88.9M | -$78.5M |
| Operating Expenses | $121.2M | $141.2M | $123.2M |
| Nonoperating Income Expense | $8.1M | $5.3M | $18.3M |
| Income Tax Expense Benefit | -$58.0K | -$5.5M | $8.0M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$87.9M | -$83.6M | -$60.2M |
| General And Administrative Expense | $26.8M | $32.0M | $28.8M |
| Comprehensive Income Net Of Tax | -$88.3M | -$77.3M | -$68.1M |
| Amortization Of Non Cash Collaborations Revenue | $212.0K | $1.7M | $742.0K |
| Asset Impairment Charges | $1.0M | $23.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$20.4M | -$19.9M | -$25.0M | -$18.8M | -$10.7M | -$25.1M | -$19.8M | -$13.0M | -$16.1M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$1.0K | -$249.0K | -$88.0K | $1.9M | $13.0K | -$181.0K | $70.00 | -$176.0K | $21.0K |
| Revenue From Contract With Customer Excluding Assessed Tax | $8.7M | $8.5M | $4.1M | $11.5M | $20.0M | $11.2M | $12.4M | $11.3M | $8.7M |
| Research And Development Expense | $25.3M | $22.5M | $25.1M | $26.3M | $28.3M | $31.4M | $26.8M | $22.7M | $20.1M |
| Other Nonoperating Income Expense | -$2.0K | -$70.0K | -$8.0K | -$57.0K | -$51.0K | -$50.0K | -$85.0K | $16.0K | -$1.0K |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$1.0K | -$249.0K | -$88.0K | $1.9M | $13.0K | -$181.0K | $70.0K | -$176.0K | $21.0K |
| Operating Income Loss | -$22.8M | -$21.0M | -$27.8M | -$22.4M | -$16.9M | -$29.0M | -$22.4M | -$18.0M | -$17.9M |
| Operating Expenses | $31.5M | $29.5M | $31.9M | $33.9M | $36.9M | $40.2M | $34.8M | $29.3M | $26.6M |
| Nonoperating Income Expense | $2.2M | $1.1M | $2.9M | $1.5M | $3.9M | $3.9M | $3.8M | $6.9M | $4.0M |
| Income Tax Expense Benefit | -$234.0K | $44.0K | $98.0K | -$2.1M | -$2.2M | $0.00 | $1.2M | $1.9M | -$2.2M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$20.6M | -$19.9M | -$24.9M | -$20.9M | -$12.9M | -$25.1M | -$18.6M | -$11.1M | -$13.9M |
| General And Administrative Expense | $6.2M | $7.0M | $6.8M | $7.6M | $8.6M | $8.8M | $7.9M | $6.6M | $6.5M |
| Comprehensive Income Net Of Tax | -$20.4M | -$20.2M | -$25.1M | -$16.9M | -$10.7M | -$25.3M | -$19.8M | -$13.2M | -$16.1M |
| Amortization Of Non Cash Collaborations Revenue | $77.0K | $30.0K | $78.0K | ||||||
| Asset Impairment Charges | $0.00 | $4.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $158.6M | $234.9M | -$135.6M | -$74.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $46.9M | $32.6M | $145.9M | $190.5M |
| Cash And Cash Equivalents At Carrying Value | $41.7M | $27.4M | $140.6M | |
| Change In Fair Value Of Long Term Investments | $1.3M | $9.2M | -$2.9M | |
| Retained Earnings Accumulated Deficit | -$310.9M | -$223.0M | -$144.9M | |
| Restricted Cash Noncurrent | $5.2M | $5.2M | $5.2M | |
| Restricted Cash | $5.2M | $5.2M | $5.2M | |
| Receivables Net Current | $305.0K | $1.3M | $2.5M | |
| Property Plant And Equipment Net | $12.3M | $17.7M | $21.5M | |
| Prepaid Expense And Other Assets Current | $4.4M | $8.4M | $4.6M | |
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | |
| Other Liabilities Noncurrent | $2.0M | $2.0M | $5.1M | |
| Other Assets Noncurrent | $836.0K | $287.0K | $5.5M | |
| Operating Lease Right Of Use Asset | $35.1M | $39.9M | $43.6M | |
| Operating Lease Liability Noncurrent | $34.6M | $40.2M | $44.8M | |
| Operating Lease Liability Current | $6.0M | $5.6M | $3.4M | |
| Operating Lease Expense | $5.3M | $4.6M | $4.2M | |
| Long Term Investments | $2.2M | $3.4M | $10.7M | |
| Liabilities Current | $22.9M | $37.3M | $68.9M | |
| Liabilities And Stockholders Equity | $221.1M | $324.6M | $364.8M | |
| Liabilities | $62.5M | $89.7M | $149.7M | |
| Contract With Customer Liability Noncurrent | $3.0M | $10.2M | $30.9M | |
| Contract With Customer Liability Current | $8.7M | $22.8M | $48.1M | |
| Common Stock Value | $4.0K | $4.0K | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $14.3M | -$113.2M | -$44.7M | |
| Available For Sale Securities Debt Securities Current | $119.1M | $220.9M | $130.6M | |
| Assets Current | $165.5M | $258.0M | $278.3M | |
| Assets | $221.1M | $324.6M | $364.8M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $260.0K | $709.0K | -$97.0K | |
| Accrued Liabilities And Other Liabilities | $6.7M | $8.4M | $11.5M | |
| Accretion Amortization Of Discounts And Premiums Investments | $3.0M | $6.2M | $8.5M | |
| Accounts Payable Current | $1.5M | $533.0K | $1.8M | |
| Reclassification Of Deferred Offering Costs Paid | $3.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $178.4M | $195.8M | $212.7M | $255.8M | $269.4M | $275.6M | -$119.0K | -$102.5M | -$90.0M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $38.0M | $32.1M | $34.4M | $30.4M | $66.4M | $107.8M | $107.1M | $56.9M | $101.7M |
| Cash And Cash Equivalents At Carrying Value | $32.8M | $26.9M | $29.2M | $25.1M | $61.2M | $102.6M | $101.9M | $51.6M | $95.7M |
| Change In Fair Value Of Long Term Investments | $0.00 | $1.3M | $2.1M | $0.00 | $0.00 | -$2.9M | |||
| Retained Earnings Accumulated Deficit | -$288.3M | -$267.9M | -$248.0M | -$199.6M | -$180.8M | -$170.1M | |||
| Restricted Cash Noncurrent | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M | |||
| Restricted Cash | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M | $6.1M |
| Receivables Net Current | $960.0K | $873.0K | $1.0M | $589.0K | $1.6M | $2.1M | |||
| Property Plant And Equipment Net | $13.9M | $15.1M | $16.5M | $19.7M | $20.7M | $21.0M | |||
| Prepaid Expense And Other Assets Current | $4.7M | $5.8M | $6.2M | $7.1M | $6.0M | $6.2M | |||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Other Liabilities Noncurrent | $1.9M | $2.2M | $2.1M | $3.1M | $3.8M | $5.1M | |||
| Other Assets Noncurrent | $809.0K | $805.0K | $781.0K | $320.0K | $332.0K | $379.0K | |||
| Operating Lease Right Of Use Asset | $36.0M | $37.3M | $38.7M | $40.2M | $41.4M | $42.5M | |||
| Operating Lease Liability Noncurrent | $36.1M | $37.5M | $38.8M | $41.4M | $42.5M | $43.7M | |||
| Operating Lease Liability Current | $5.6M | $5.5M | $5.6M | $4.7M | $5.4M | $4.4M | |||
| Operating Lease Expense | $1.3M | $1.1M | $983.0K | ||||||
| Long Term Investments | $2.2M | $2.2M | $3.4M | $10.6M | $10.7M | $10.7M | |||
| Liabilities Current | $29.6M | $33.3M | $39.9M | $45.7M | $52.8M | $70.7M | |||
| Liabilities And Stockholders Equity | $247.9M | $272.3M | $297.9M | $358.3M | $385.9M | $415.4M | |||
| Liabilities | $69.5M | $76.5M | $85.2M | $102.6M | $116.5M | $139.8M | |||
| Contract With Customer Liability Noncurrent | $1.9M | $3.6M | $4.4M | $12.4M | $17.3M | $20.3M | |||
| Contract With Customer Liability Current | $12.9M | $18.9M | $25.5M | $29.1M | $33.0M | $48.3M | |||
| Common Stock Value | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.8M | -$38.0M | -$88.8M | ||||||
| Available For Sale Securities Debt Securities Current | $151.3M | $178.1M | $196.8M | $249.5M | $238.7M | $224.8M | |||
| Assets Current | $189.8M | $211.7M | $233.2M | $282.3M | $307.6M | $335.6M | |||
| Assets | $247.9M | $272.3M | $297.9M | $358.3M | $385.9M | $415.4M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $371.0K | $372.0K | $621.0K | $1.6M | -$265.0K | -$278.0K | |||
| Accrued Liabilities And Other Liabilities | $9.9M | $5.9M | $6.1M | $8.8M | $11.0M | $7.1M | |||
| Accretion Amortization Of Discounts And Premiums Investments | $1.0M | $1.2M | $2.2M | ||||||
| Accounts Payable Current | $1.2M | $2.9M | $2.7M | $3.1M | $3.5M | $6.8M | |||
| Reclassification Of Deferred Offering Costs Paid | $0.00 | $3.3M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $11.9M | $16.2M | $6.9M |
| Proceeds From Sale And Maturity Of Marketable Securities | $170.5M | $221.4M | $263.6M |
| Payments To Acquire Property Plant And Equipment | $574.0K | $3.1M | $9.8M |
| Payments To Acquire Marketable Securities | $66.4M | $306.1M | $208.1M |
| Net Cash Provided By Used In Operating Activities | -$88.9M | -$109.1M | -$91.4M |
| Net Cash Provided By Used In Investing Activities | $103.5M | -$88.2M | $45.7M |
| Net Cash Provided By Used In Financing Activities | -$356.0K | $84.0M | $1.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$4.3M | $2.3M | $1.1M |
| Increase Decrease In Operating Lease Liability | -$5.6M | -$3.4M | -$1.2M |
| Increase Decrease In Deferred Revenue And Collaboration Advance | -$21.1M | -$46.8M | -$30.3M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$1.6M | -$893.0K | $1.6M |
| Increase Decrease In Accounts Payable | $1.1M | -$1.1M | -$84.0K |
| Increase Decrease In Accounts Receivable | -$952.0K | -$1.2M | $2.5M |
| Increase Decrease In Other Noncurrent Liabilities | -$58.0K | -$3.1M | $4.0M |
| Increase Decrease In Accrued Income Taxes Payable | -$3.3M | $1.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Share Based Compensation | $2.9M | $5.1M | $529.0K |
| Proceeds From Sale And Maturity Of Marketable Securities | $47.3M | $80.8M | $49.8M |
| Payments To Acquire Property Plant And Equipment | $288.0K | $915.0K | $2.7M |
| Payments To Acquire Marketable Securities | $22.3M | $174.7M | $119.2M |
| Net Cash Provided By Used In Operating Activities | -$22.8M | -$29.9M | -$21.0M |
| Net Cash Provided By Used In Investing Activities | $24.7M | -$94.7M | -$72.1M |
| Net Cash Provided By Used In Financing Activities | -$77.0K | $86.5M | $4.3M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$2.2M | $938.0K | $97.0K |
| Increase Decrease In Operating Lease Liability | -$1.4M | -$179.0K | -$467.0K |
| Increase Decrease In Deferred Revenue And Collaboration Advance | -$3.0M | -$10.4M | -$7.8M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$2.6M | -$3.0M | -$1.3M |
| Increase Decrease In Accounts Payable | $2.2M | $3.2M | $1.2M |
| Increase Decrease In Accounts Receivable | -$245.0K | -$369.0K | |
| Increase Decrease In Other Noncurrent Liabilities | $98.0K | $260.0K | |
| Increase Decrease In Accrued Income Taxes Payable | $1.9M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 37.3M | 33.0M | 3.4M |
| Weighted Average Number Of Diluted Shares Outstanding | 37.3M | 33.0M | 3.4M |
| Earnings Per Share Diluted | $-2.36 | $-2.36 | $-20.05 |
| Earnings Per Share Basic | $-2.36 | $-2.36 | $-20.05 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 37.6M | 37.4M | 3.4M |
| Common Stock Shares Issued | 37.6M | 37.4M | 3.4M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 66.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 37.3M | 37.2M | 37.0M | 36.8M | 36.6M | 21.1M | 3.4M | 3.4M | 3.4M |
| Weighted Average Number Of Diluted Shares Outstanding | 37.3M | 37.2M | 37.0M | 36.8M | 36.6M | 21.1M | 3.4M | 3.4M | 3.4M |
| Earnings Per Share Diluted | $-0.55 | $-0.54 | $-0.68 | $-0.51 | $-0.29 | $-1.19 | $-5.82 | $-3.82 | $-4.74 |
| Earnings Per Share Basic | $-0.55 | $-0.54 | $-0.68 | $-0.51 | $-0.29 | $-1.19 | $-5.82 | $-3.82 | $-4.74 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 37.5M | 37.5M | 37.4M | 37.4M | 37.5M | 37.5M | |||
| Common Stock Shares Issued | 37.5M | 37.5M | 37.4M | 37.4M | 37.5M | 37.5M | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $11.9M | $16.2M | $6.9M |
| Investment Income Interest | $9.5M | $14.7M | $15.5M |
| Depreciation | $5.3M | $5.4M | $4.2M |
| Additional Paid In Capital | $469.2M | $457.1M | $9.5M |
| Capital Expenditures Incurred But Not Yet Paid | $171.0K | $638.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.0M | $3.2M | $2.9M | $3.2M | $4.5M | $5.1M | $3.3K | $656.0K | $529.0K |
| Investment Income Interest | $2.2M | $2.5M | $2.9M | $3.6M | $4.0M | $3.9M | $3.9M | $4.0M | $4.0M |
| Depreciation | $1.4M | $1.3M | $841.0K | ||||||
| Additional Paid In Capital | $466.4M | $463.4M | $460.1M | $453.7M | $450.5M | $446.0M | |||
| Capital Expenditures Incurred But Not Yet Paid | $23.0K | $418.0K | $1.4M |
Most recent annual filing with the SEC: March 5, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.